The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances
Open accessAbstract
Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration approval, interest in OVs has been boosted greatly. Nevertheless, despite extensive research, oncolytic virotherapy has shown limited efficacy against solid tumors. Recent advances in viral retargeting, genetic editing, viral delivery platforms, tracking strategies, OV-based gene therapy, and combination strategies have the potential to broaden the applications of oncolytic virotherapy in oncology. In this review, we present several insights into the limitations and challenges of oncolytic virotherapy, describe the strategies mentioned above, provide a summary of recent preclinical and clinical trials in the field of oncolytic virotherapy, and highlight the need to optimize current strategies to improve clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
The Role of Hypoxia-Induced Factors in Tumor Progression
Vaupel, P. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90005-10 · Cited by 827
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716435 · Cited by 815
Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 779
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
Puzanov, I., Milhem, M. M., Minor, D., Hamid, O., Li, A., Chen, L., Chastain, M., Gorski, K. S., Anderson, A., Chou, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1529 · Cited by 562
Kuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S., & Reynolds, A. R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0181-9 · Cited by 446
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
McKee, T. D., Grandi, P., Mok, W., Alexandrakis, G., Insin, N., Zimmer, J. P., Bawendi, M. G., Boucher, Y., Breakefield, X. O., & Jain, R. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2242 · Cited by 397
Emerging Cellular Therapies for Cancer
Guedan, S., Ruella, M., & June, C. H. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041407 · Cited by 386
Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
Fisher, K., Stallwood, Y., Green, N., Ulbrich, K., Mautner, V, & Seymour, L. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301389 · Cited by 316
Oncolytic virus immunotherapy: future prospects for oncology
Raja, J., Ludwig, J. M., Gettinger, S. N., Schalper, K. A., & Kim, H. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0458-z · Cited by 313
Watanabe, K., Luo, Y., Da, T., Guedan, S., Ruella, M., Scholler, J., Keith, B., Young, R. M., Engels, B., Sorsa, S., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99573 · Cited by 283
Packiam, V. T., Lamm, D. L., Barocas, D. A., Trainer, A., Fand, B., Davis, R. L., Clark, W., Kroeger, M., Dumbadze, I., Chamie, K., et al. (2018) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.07.005 · Cited by 249
Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines
Russell, S. J., & Barber, G. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.011 · Cited by 244
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
Melcher, A., Parato, K., Rooney, C. M., & Bell, J. C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.65 · Cited by 232
Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies
Gujar, S., Pol, J. G., Kim, Y., Lee, P. W., & Kroemer, G. (2018) · Trends in Immunology · doi:10.1016/j.it.2017.11.006 · Cited by 231
Brown, M. C., Holl, E. K., Boczkowski, D., Dobrikova, E., Mosaheb, M., Chandramohan, V., Bigner, D. D., Gromeier, M., & Nair, S. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4220 · Cited by 224
Tanoue, K., Rosewell Shaw, A., Watanabe, N., Porter, C., Rana, B., Gottschalk, S., Brenner, M., & Suzuki, M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1577 · Cited by 219
Rosewell Shaw, A., Porter, C. E., Watanabe, N., Tanoue, K., Sikora, A., Gottschalk, S., Brenner, M. K., & Suzuki, M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.010 · Cited by 219
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
Gulley, J. L., Madan, R. A., Pachynski, R., Mulders, P., Sheikh, N. A., Trager, J., & Drake, C. G. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw261 · Cited by 215
Guedan, S., Rojas, J. J., Gros, A., Mercade, E., Cascallo, M., & Alemany, R. (2010) · Molecular Therapy · doi:10.1038/mt.2010.79 · Cited by 204
Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus
Green, N. K., Herbert, C. W., Hale, S. J., Hale, A. B., Mautner, V, Harkins, R., Hermiston, T., Ulbrich, K., Fisher, K. D., & Seymour, L. W. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302295 · Cited by 204
Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer
Kuhn, I., Harden, P., Bauzon, M., Chartier, C., Nye, J., Thorne, S., Reid, T., Ni, S., Lieber, A., Fisher, K., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002409 · Cited by 200
Current Issues and Future Directions of Oncolytic Adenoviruses
Yamamoto, M., & Curiel, D. T. (2010) · Molecular Therapy · doi:10.1038/mt.2009.266 · Cited by 197
Jiang, H., Rivera-Molina, Y., Gomez-Manzano, C., Clise-Dwyer, K., Bover, L., Vence, L. M., Yuan, Y., Lang, F. F., Toniatti, C., Hossain, M. B., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0468 · Cited by 197
DiPaola, R., Plante, M., Kaufman, H., Petrylak, D., Israeli, R., Lattime, E., Manson, K., & Schuetz, T. (2006) · Journal of Translational Medicine · doi:10.1186/1479-5876-4-1 · Cited by 191
Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
Nayyar, G., Chu, Y., & Cairo, M. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00051 · Cited by 177
Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds
Sivanandam, V., LaRocca, C. J., Chen, N. G., Fong, Y., & Warner, S. G. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.04.003 · Cited by 176
de Sostoa, J., Fajardo, C. A., Moreno, R., Ramos, M. D. B., Farrera-Sal, M., & Alemany, R. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0505-4 · Cited by 167
Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides
Peng, K.-W., Facteau, S., Wegman, T., O'Kane, D., & Russell, S. J. (2002) · Nature Medicine · doi:10.1038/nm0502-527 · Cited by 162
CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
Guedan, S., & Alemany, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02460 · Cited by 162
Lun, X. Q., Jang, J.-H., Tang, N., Deng, H., Head, R., Bell, J. C., Stojdl, D. F., Nutt, C. L., Senger, D. L., Forsyth, P. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2342 · Cited by 158
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy
Fajardo, C. A., Guedan, S., Rojas, L. A., Moreno, R., Arias-Badia, M., de Sostoa, J., June, C. H., & Alemany, R. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1708 · Cited by 155
Zamarin, D., Holmgaard, R., Ricca, J. M., Plitt, T., Palese, P., Sharma, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2017) · Nature Communications · doi:10.1038/ncomms14340 · Cited by 152
Muik, A., Stubbert, L. J., Jahedi, R. Z., Geiβ, Y., Kimpel, J., Dold, C., Tober, R., Volk, A., Klein, S., Dietrich, U., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3306 · Cited by 145
Passaro, C., Alayo, Q. A., DeLaura, I. F., McNulty, J., Grauwet, K., Ito, H., Bhaskaran, V., Mineo, M., Lawler, S. E., Shah, K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2311 · Cited by 132
Duebgen, M., Martínez‐Quintanilla, J., Tamura, K., Hingtgen, S., Redjal, N., Wakimoto, H., & Shah, K. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju090 · Cited by 131
Ulasov, I. V., Zhu, Z. B., Tyler, M. A., Han, Y., Rivera, Á. A., Khramtsov, A., Curiel, D. T., & Lesniak, M. S. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.002 · Cited by 126
Prospects for combined use of oncolytic viruses and CAR T-cells
Ajina, A., & Maher, J. F. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0294-6 · Cited by 121
Kreppel, F., Gackowski, J., Schmidt, E., & Kochanek, S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.006 · Cited by 119
Foloppe, J., Kintz, J., Futin, N., Findeli, A., Cordier, P., Schlesinger, Y., Hoffmann, C., Tosch, C., Balloul, J.-M., & Erbs, P. (2008) · Gene Therapy · doi:10.1038/gt.2008.82 · Cited by 119
Yang, D., Chung, Y.-C., Lai, Y., Lai, C., Liu, H., & Hu, Y. (2007) · Molecular Therapy · doi:10.1038/mt.sj.6300131 · Cited by 116
Doronin, K., Shashkova, E. V., May, S. M., Hofherr, S. E., & Barry, M. A. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.028 · Cited by 116
Patel, M. R., Jacobson, B. A., Ji, Y., Drees, J. J., Tang, S., Xiong, K., Wang, H., Prigge, J. E., Dash, A. S., Kratzke, A. K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5320 · Cited by 114
Bridle, B. W., Boudreau, J. E., Lichty, B. D., Brunellière, J., Stephenson, K. B., Koshy, S. T., Bramson, J. L., & Wan, Y. (2009) · Molecular Therapy · doi:10.1038/mt.2009.154 · Cited by 111
Enhanced Antitumor Efficacy of Vasculostatin (Vstat120) Expressing Oncolytic HSV-1
Hardcastle, J. J., Kurozumi, K., Dmitrieva, N., Sayers, M. P., Ahmad, S. B., Waterman, P. R., Weissleder, R., Chiocca, E. A., & Kaur, B. (2009) · Molecular Therapy · doi:10.1038/mt.2009.232 · Cited by 109
Menotti, L., Cerretani, A., Hengel, H., & Campadelli‐Fiume, G. (2008) · Journal of Virology · doi:10.1128/jvi.01133-08 · Cited by 108
Li, R., Xiaohua, T., Li, Y., Zhang, H., Ma, R., Ji, T., Dong, W., Tong, T., Liu, Y., Chen, D., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.02.025 · Cited by 105
Kuryk, Ł., Møller, A. W., & Jaderberg, M. E. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1532763 · Cited by 102
Cancer-fighting viruses win approval
Ledford, H. K. (2015) · Nature · doi:10.1038/526622a · Cited by 101
Oncolytic vesicular stomatitis virus expressing interferon-σ has enhanced therapeutic activity
Bourgeois‐Daigneault, M., Roy, D. G., Falls, T. J., Twumasi‐Boateng, K., St-Germain, L. E., Marguerie, M., Garcia, V., Selman, M., Jennings, V. A., Pettigrew, J. L., et al. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.1 · Cited by 99
TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response
Han, J., Chen, X., Chu, J., Xu, B., Meisen, W. H., Chen, L., Zhang, L., Zhang, J., He, X., Wang, Q.-E., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0894 · Cited by 98
Achieving systemic delivery of oncolytic viruses
Hill, C., & Carlisle, R. C. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1617269 · Cited by 89
Chondroitinase ABC I–Mediated Enhancement of Oncolytic Virus Spread and Antitumor Efficacy
Dmitrieva, N., Yu, L., Viapiano, M. S., Cripe, T. P., Chiocca, E. A., Glorioso, J. C., & Kaur, B. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2213 · Cited by 88
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors
Pol, J. G., Lévesque, S., Workenhe, S. T., Gujar, S. A., Bœuf, F. L., Clements, D. R., Fahrner, J., Fend, L., Bell, J. C., Mossman, K. L., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1503032 · Cited by 84
Nishio, N., & Dotti, G. (2015) · OncoImmunology · doi:10.4161/21505594.2014.988098 · Cited by 83
Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches
Goradel, N. H., Mohajel, N., Malekshahi, Z. V., Jahangiri, S., Najafi, M., Farhood, B., Mortezaee, K., Negahdari, B., & Arashkia, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27850 · Cited by 83
Greco, A., Benedetto, A. D., Howard, C. M., Kelly, S., Nande, R. P., Dementieva, Y. A., Miranda, M., Brunetti, A., Salvatore, M., Claudio, L., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.252 · Cited by 80
Olagnier, D. P., Lababidi, R. R., Hadj, S. B., Sze, A., Liu, Y., Naidu, S. D., Ferrari, M., Jiang, Y., Chiang, C., Beljanski, V., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.022 · Cited by 79
GM-CSF Production by Tumor Cells Is Associated with Improved Survival in Colorectal Cancer
Nebiker, C. A., Han, J., Eppenberger‐Castori, S., Iezzi, G., Hirt, C., Amicarella, F., Cremonesi, E., Huber, X., Padovan, E., Angrisani, B., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2774 · Cited by 78
Myeloid-Derived Suppressor Cells as a Vehicle for Tumor-Specific Oncolytic Viral Therapy
Eisenstein, S. G., Coakley, B. A., Briley-Saebo, K. C., Ma, G., Chen, H.-M., Meseck, M. L., Ward, S., Divino, C. M., Woo, S. L. C., Chen, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1597 · Cited by 78
PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance
Russell, L., Swanner, J. L., Jaime‐Ramirez, A. C., Wang, Y., Sprague, A. C., Banasavadi‐Siddegowda, Y., Yoo, J. Y., Sizemore, G. M., Kladney, R. D., Zhang, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07344-1 · Cited by 75
Polymeric oncolytic adenovirus for cancer gene therapy
Choi, J.-W., Lee, Y. S., Yun, C., & Kim, S. W. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.009 · Cited by 73
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer
Hamid, O., Hoffner, B., Gasal, E., Hong, J. J., & Carvajal, R. D. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2025-8 · Cited by 70
Totsch, S. K., Schlappi, C., Kang, K., Ishizuka, A. S., Lynn, G. M., Fox, B. M., Beierle, E. A., Whitley, R. J., Markert, J. M., Gillespie, G. Y., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0870-y · Cited by 68
Combining Oncolytic Adenovirus with Radiation—A Paradigm for the Future of Radiosensitization
O'Cathail, S. M., Pokrovska, T. D., Maughan, T., Fisher, K. D., Seymour, L. W., & Hawkins, M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00153 · Cited by 62
Guse, K., Słoniecka, M., Diaconu, I., Ottolino‐Perry, K., Tang, N., Ng, C. S. H., Boeuf, F. L., Bell, J. C., McCart, J. A., Ristimäki, A., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00692-09 · Cited by 61
Dynamic Monitoring of Oncolytic Adenovirus In Vivo by Genetic Capsid Labeling
Le, L. P., Le, H. N., Dmitriev, I. P., Davydova, J. G., Gavrikova, T. A., Yamamoto, S., Curiel, D. T., & Yamamoto, M. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj022 · Cited by 59
Mooney, R., Majid, A. A., Batalla‐Covello, J., Machado, D., Liu, X., Gonzaga, J. M., Tirughana, R., Hammad, M., Dellinger, T. H., Lesniak, M. S., et al. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.12.003 · Cited by 59
Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy
Bressy, C., Hastie, E. L., & Grdzelishvili, V. Z. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2017.03.002 · Cited by 58
Oh, E., Hong, J., Kwon, O., & Yun, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-19300-6 · Cited by 57
Kang, Y.-A., Shin, H.-C., Yoo, J. Y., Kim, J.-H., Kim, J.-H., Kim, J., Kim, J., & Yun, C. (2008) · Molecular Therapy · doi:10.1038/mt.2008.63 · Cited by 55
Xiao, T., Fan, J. K., Huang, H. L., Gu, J. F., Li, L., & Liu, X. (2009) · Cell Research · doi:10.1038/cr.2009.126 · Cited by 55
Fusogenic Viruses in Oncolytic Immunotherapy
Krabbe, T., & Altomonte, J. (2018) · Cancers · doi:10.3390/cancers10070216 · Cited by 53
pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis
Choi, J.-W., Jung, S.-J., Kasala, D., Hwang, J. K., Hu, J., Bae, Y. H., & Yun, C. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.005 · Cited by 51
Roulstone, V., Pedersen, M., Kyula, J., Mansfield, D., Khan, A., McEntee, G., Wilkinson, M., Karapanagiotou, E. M., Coffey, M. C., Marais, R., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.15 · Cited by 51
Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes
Rouanet, M., Lebrin, M., Gross, F., Bournet, B., Cordelier, P., & Buscail, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061231 · Cited by 50
Characterization of Magnetic Viral Complexes for Targeted Delivery in Oncology
Almstätter, I., Mykhaylyk, O. M., Settles, M., Altomonte, J., Aichler, M., Walch, A. K., Rummeny, E. J., Ebert, O., Plank, C., & Braren, R. (2015) · Theranostics · doi:10.7150/thno.10438 · Cited by 49
Perspectives on immunotherapy via oncolytic viruses
Reale, A., Vitiello, A., Conciatori, V., Parolin, C., Calistri, A., & Palù, G. (2019) · Infectious Agents and Cancer · doi:10.1186/s13027-018-0218-1 · Cited by 47
Adelfinger, M., Bessler, S., Frentzen, A., Cecil, A., Langbein-Laugwitz, J., Gentschev, I., & Szalay, A. A. (2015) · Viruses · doi:10.3390/v7072811 · Cited by 46
Guedan, S., Grases, D., Rojas, J. J., Gros, A., Vilardell, F., Vile, R. G., Mercadé, E., Cascalló, M., & Alemany, R. (2011) · Gene Therapy · doi:10.1038/gt.2011.184 · Cited by 46
Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
Zamarin, D., & Wolchok, J. D. (2014) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2014.4 · Cited by 46
Andtbacka, R. H. I., Curti, B. D., Hallmeyer, S., Feng, Z., Paustian, C. C., Bifulco, C. B., Fox, B. A., Grose, M., & Shafren, D. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p343 · Cited by 39
Wu, Y., He, J., Geng, J., An, Y., Ye, X., Yan, S., Yu, Q., Yin, J., Zhang, Z., & Li, D. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.02.042 · Cited by 38
Armstrong, L., Arrington, A. K., Han, J., Gavrikova, T. A., Brown, E., Yamamoto, M., Vickers, S. M., & Davydova, J. (2012) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2012.02.016 · Cited by 37
Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization
Sharp, D. W., & Lattime, E. C. (2016) · Biomedicines · doi:10.3390/biomedicines4030019 · Cited by 36
Koval, O. A., Kochneva, G. V., Tkachenko, A., Troitskaya, O. S., Sivolobova, G. F., Grazhdantseva, A. A., Nushtaeva, A. A., Kuligina, E. V., & Richter, V. A. (2017) · BioMed Research International · doi:10.1155/2017/3620510 · Cited by 35
Simpson, G. R., Horvath, A. A., Annels, N. E., Pencavel, T. D., Metcalf, S., Seth, R., Peschard, P., Price, T., Coffin, R. S., Mostafid, H. A., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.577 · Cited by 34
Hesse, A., Kosmides, D., Kontermann, R. E., et al. (2006) · Journal of Virology · doi:10.1128/jvi.02722-06 · Cited by 34
He, X., Su, C., Wang, X., Pan, X., Tu, Z., Gong, Y.-F., Gao, J., Liao, Z., Jin, J., Wu, H., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.05.006 · Cited by 31
Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo
Guse, K., Dias, J. D., Bauerschmitz, G. J., Hakkarainen, T., Aavik, E., Ranki, T., Pisto, T., Särkioja, M., Desmond, R. A., Kanerva, A., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302949 · Cited by 30
Hutzler, S., Erbar, S., Jabulowsky, R. A., Hanauer, J. R. H., Schnotz, J. H., Beißert, T., Bodmer, B. S., Eberle, R., Böller, K., Klamp, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16928-8 · Cited by 29
Progress in gene therapy using oncolytic vaccinia virus as vectors
Yang, X., Huang, B., Deng, L., & Hu, Z. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2762-x · Cited by 29
Haddad, D. R., Chen, C., Carlin, S., Silberhumer, G. R., Chen, N. G., Zhang, Q., Longo, V. A., Carpenter, S. G., Mittra, A., Carson, J. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041647 · Cited by 25
Impact of E1a Modifications on Tumor-Selective Adenoviral Replication and Toxicity
Sauthoff, H., Pipiya, T., Heitner, S., Chen, S., Bleck, B., Reibman, J., Chang, W., Norman, R. G., Rom, W. N., & Hay, J. G. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.014 · Cited by 24
Dinsart, C., Pervolaraki, K., Stroh-Dege, A., Lavie, M., Ronsse, I., Rommelaere, J., Damme, J. V., Raemdonck, K. V., & Struyf, S. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.108 · Cited by 13
Cited by
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
Gavilán, H., Avugadda, S. K., Fernández-Cabada, T., Soni, N., Cassani, M., Mai, B. T., Chantrell, R., & Pellegrino, T. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00427a · Cited by 525
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023) · Advanced Materials · doi:10.1002/adma.202303261 · Cited by 477
Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy
Galli, F., Aguilera, J. V., Palermo, B., Markovic, S. N., Nisticò, P., & Signore, A. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01586-y · Cited by 278
Next-generation stem cells — ushering in a new era of cell-based therapies
Kimbrel, E. A., & Lanza, R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0064-x · Cited by 275
Metadata
- Authors
- Zheng, M., Huang, J., Tong, A., & Yang, H.
- Venue
- Molecular Therapy - Oncolytics
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 15
- Pages
- 234-247
- ISSN
- 2372-7705 (ISSN-L)
- OpenAlex
- W2984628891
- Cited by
- 295
- References
- 101
- FWCI
- 16.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.